

David Hough

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11816080/publications.pdf>

Version: 2024-02-01

38
papers

4,324
citations

304743

22
h-index

315739

38
g-index

38
all docs

38
docs citations

38
times ranked

1840
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. <i>American Journal of Psychiatry</i> , 2019, 176, 428-438.	7.2	557
2	Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study. <i>American Journal of Psychiatry</i> , 2018, 175, 620-630.	7.2	496
3	Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression. <i>JAMA Psychiatry</i> , 2019, 76, 893.	11.0	472
4	Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1). <i>International Journal of Neuropsychopharmacology</i> , 2019, 22, 616-630.	2.1	404
5	Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depressionâ€”TRANSFORM-3. <i>American Journal of Geriatric Psychiatry</i> , 2020, 28, 121-141.	1.2	325
6	Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II). <i>International Journal of Neuropsychopharmacology</i> , 2021, 24, 22-31.	2.1	280
7	Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	2.2	273
8	Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled study. <i>Schizophrenia Research</i> , 2010, 116, 107-117.	2.0	225
9	A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 218-226.	4.8	146
10	Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. <i>International Journal of Neuropsychopharmacology</i> , 2010, 13, 635-647.	2.1	138
11	A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia. <i>Neuropsychopharmacology</i> , 2010, 35, 2072-2082.	5.4	131
12	Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyw018.	2.1	129
13	Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 1022-1031.	4.8	107
14	A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2012, 15, 107-118.	2.1	87
15	Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia. <i>Schizophrenia Research</i> , 2012, 138, 29-34.	2.0	82
16	Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies. <i>International Clinical Psychopharmacology</i> , 2008, 23, 343-356.	1.7	75
17	Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3â€”month formulation in patients with schizophrenia: A phaseâ€”1, singleâ€”dose, randomized, openâ€”label study. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 330-339.	2.0	63
18	Efficacy and Safety of Paliperidone Extended Release in Adolescents With Schizophrenia: A Randomized, Double-Blind Study. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2015, 54, 126-137.e1.	0.5	39

#	ARTICLE	IF	CITATIONS
19	A single-dose, open-label, parallel, randomized, dose-proportionality study of paliperidone after intramuscular injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophrenia. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 1048-1057.	2.0	36
20	Approval of esketamine for treatment-resistant depression. <i>Lancet Psychiatry</i> , 2020, 7, 232-235.	7.4	29
21	Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia. <i>Current Medical Research and Opinion</i> , 2015, 31, 2043-2054.	1.9	28
22	Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2011, 7, 93.	2.2	25
23	Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 1381.	2.2	21
24	Pharmacokinetic profile after multiple deltoid or gluteal intramuscular injections of paliperidone palmitate in patients with schizophrenia. <i>Clinical Pharmacology in Drug Development</i> , 2015, 4, 270-278.	1.6	19
25	Benefit-Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant Depression. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 536-546.	4.7	17
26	Long-Term Safety of Paliperidone Extended Release in Adolescents with Schizophrenia: An Open-Label, Flexible Dose Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2015, 25, 548-557.	1.3	15
27	Comparison of Long-Term Efficacy and Safety of Esketamine Nasal Spray Plus Oral Antidepressant in Younger Versus Older Patients With Treatment-Resistant Depression: Post-Hoc Analysis of SUSTAIN-2, a Long-Term Open-Label Phase 3 Safety and Efficacy Study. <i>American Journal of Geriatric Psychiatry</i> , 2022, 30, 541-556.	1.2	14
28	An Analysis of Potentially Prolactin-Related Adverse Events and Abnormal Prolactin Values in Randomized Clinical Trials with Paliperidone Palmitate. <i>Annals of Pharmacotherapy</i> , 2012, 46, 1322-1330.	1.9	13
29	Baseline characteristics and treatment-emergent risk factors associated with cerebrovascular event and death with risperidone in dementia patients. <i>British Journal of Psychiatry</i> , 2016, 209, 378-384.	2.8	13
30	Paliperidone palmitate: Japanese postmarketing mortality results in patients with schizophrenia. <i>Current Medical Research and Opinion</i> , 2016, 32, 1671-1679.	1.9	12
31	Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 2193-2207.	2.2	11
32	Comment on a Word to the Wise About Intranasal Esketamine. <i>American Journal of Psychiatry</i> , 2019, 176, 856-857.	7.2	8
33	Patient preferences for ketamine-based antidepressant treatments in treatment-resistant depression: Results from a clinical trial and panel. <i>Neurology Psychiatry and Brain Research</i> , 2020, 37, 67-78.	2.0	8
34	Efficacy and Safety of Paliperidone Extended Release 1.5 mg/day-A Double-blind, Placebo- and Active-Controlled, Study in the Treatment of Patients with Schizophrenia. <i>Psychopharmacology Bulletin</i> , 2011, 44, 54-72.	0.0	8
35	A Post-hoc comparison of paliperidone palmitate to oral risperidone during initiation of long-acting risperidone injection in patients with acute schizophrenia. <i>Innovations in Clinical Neuroscience</i> , 2011, 8, 26-33.	0.1	6
36	Paliperidone Palmitate Long-Acting Injectable Given Intramuscularly in the Deltoid Versus the Gluteal Muscle. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 744-745.	1.4	5

#	ARTICLE	IF	CITATIONS
37	<p>Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population</p>. Neuropsychiatric Disease and Treatment, 2019, Volume 15, 587-602.	2.2	4
38	Cognitive functioning in adolescents with schizophrenia treated with paliperidone extended-release: 6-Month exploratory analysis from an open-label, single-arm safety study. Schizophrenia Research: Cognition, 2020, 20, 100173.	1.3	3